MEDVi QUAD Review 2026: The New Formula's 4 Ingredients, Analyzed

MEDVi changed QUAD's formula in July 2026. Vardenafil and apomorphine are out; L-citrulline and PT-141 are in. We went through the published evidence for each of the four current ingredients, compared the new formula against Rugiet Ready and BlueChew Gold, and separated what the science supports from what is marketing.

What Is MEDVi QUAD?

MEDVi QUAD is a compounded sublingual liquid ED medication that combines four active pharmaceutical ingredients into a single dose. It is prescribed through MEDVi's telehealth platform, where a licensed clinician reviews your medical history and determines appropriate dosing.

As of July 16, 2026, the "QUAD" name refers to a different set of four ingredients than it did earlier this year: sildenafil (the active ingredient in Viagra), tadalafil (the active ingredient in Cialis), L-citrulline (an amino acid that raises nitric-oxide production), and PT-141, also called bremelanotide (a melanocortin receptor agonist that acts on desire through the brain). Vardenafil and apomorphine are no longer in the product.

Unlike Rugiet Ready's solid troches or BlueChew Gold's dissolving tablets, QUAD is delivered as a sublingual liquid — you place the measured dose under your tongue where it absorbs directly into the bloodstream. The liquid format ensures consistent absorption, eliminates temperature sensitivity issues, and allows for precise dosing adjustments.

Dosing is compounded and set by the prescribing physician, so there is no fixed public mg figure for any of the four ingredients. Be skeptical of any review that quotes exact milligram amounts for QUAD — that is not information MEDVi publishes.

What Changed in the July 2026 Reformulation

If you read a QUAD review published before mid-July 2026 — including earlier versions of this one — it described a different product. Here is the change, plainly.

Out: vardenafil (the active ingredient in Levitra) and apomorphine (a dopamine agonist that is also used in Parkinson's disease and drew media scrutiny during 2026).

In: L-citrulline and PT-141. Sildenafil and tadalafil were retained.

MEDVi also says the new formula tastes better, and that this improves prescription-approval rates. Take that for what it is — a palatability claim, not an efficacy claim — though for a sublingual product held under the tongue, taste is not a trivial detail.

Two things follow from the swap that most affiliate pages have not caught up with. First, QUAD now contains two PDE5 inhibitors, not three. Any page still selling "triple PDE5 coverage" is describing a formula that no longer exists. Second, the "all four ingredients are FDA-approved" line is no longer accurate, because L-citrulline and PT-141 are not FDA-approved for erectile dysfunction.

How the New 4-in-1 Formula Works

The reformulated QUAD targets sexual function through three layers: PDE5 inhibition, nitric-oxide support upstream of it, and a separate central pathway for desire. Here's how each one works.

Layer 1: Two PDE5 inhibitors (blood flow)

Sildenafil and tadalafil are both PDE5 inhibitors with different pharmacokinetic profiles. Sildenafil is the fast-onset component. Tadalafil extends the response window up to 36 hours. Pairing them is the standard logic behind every product in this category, and it is the part of QUAD with the least controversy attached: both are FDA-approved ED drugs with decades of randomized controlled trials behind them.

Layer 2: L-citrulline (nitric-oxide amplification)

PDE5 inhibitors do not create nitric oxide — they prevent the breakdown of the downstream signal that nitric oxide starts. If nitric-oxide production is low to begin with, there is less signal to preserve. L-citrulline converts to L-arginine in the body, which raises nitric-oxide production and supports blood-vessel dilation. In other words, it feeds the same pathway the PDE5 inhibitors depend on, from one step further upstream.

The clinical evidence here is early but real. A small single-blind study (Cormio et al., Urology, 2011) in 24 men with mild ED found that oral L-citrulline improved erection hardness in 50% of men versus 8% on placebo. That is a genuine result, and it is also 24 men in a single-blind trial — not the evidence base behind sildenafil. L-citrulline is a supplement-grade amino acid, not an FDA-approved ED drug. Treat it as a nitric-oxide amplifier with early but genuine clinical evidence in mild ED, and nothing more.

Layer 3: PT-141 (desire, via the brain)

PT-141, also called bremelanotide, activates melanocortin (MC4R) receptors in the brain. It does not work on blood flow at all — it targets sexual desire and arousal centrally. That makes it the answer to a problem no PDE5 inhibitor solves: a drug that improves the plumbing does nothing about wanting sex in the first place.

PT-141 is FDA approved, but not for men and not for ED. It is approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women, given by injection. In men, early-phase trials of intranasal bremelanotide showed erectogenic effects, including in some men who did not respond to sildenafil, but it was never approved for ED — development stopped partly over blood-pressure concerns. Its use in QUAD is compounded, off-label, and prescriber-supervised.

That is a mixed picture, and it should be stated as one. What can be said fairly: PT-141 is the only desire-pathway ingredient in this product category with human clinical trial data behind it and an FDA approval in any indication. Oxytocin, the desire ingredient BlueChew Gold uses, has neither.

Ingredient Breakdown: What the Evidence Shows

Here is what is in each of the three main combination products as of late July 2026, and what each ingredient is actually supported by.

The honest read on this table: QUAD is now the only one of the three built around a desire ingredient that has human clinical trial data and an FDA approval in another indication. It is also the only one of the three where two of the four ingredients are not FDA-approved ED drugs. Which of those matters more depends on what you are trying to fix — and neither point is served by the "all four proven" language that still appears on a lot of affiliate pages.

QUAD vs Rugiet Ready: What's Different?

Rugiet Ready pioneered the multi-ingredient sublingual ED category in 2020 and has accumulated 1,594 Trustpilot reviews. It is an effective product with a strong track record. The differences between Rugiet and QUAD come down to three areas:

Ingredients: Rugiet uses 3 (sildenafil + tadalafil + apomorphine). QUAD uses 4, and after July 2026 the overlap is only the two PDE5 inhibitors. Where Rugiet uses apomorphine for the central piece, QUAD uses PT-141 and adds L-citrulline on top. If you want a dopamine-agonist approach to central arousal, Rugiet is where it still lives; if you want the melanocortin approach, QUAD is now the one that has it.

Delivery format: Rugiet uses a solid troche (lozenge) that dissolves under the tongue. QUAD uses a liquid. Rugiet's troches are heat-sensitive — the company asks you to store them at room temperature (74°F/23°C) or below — so they can arrive or turn soft in warm weather. Rugiet does not require refrigeration; it says to use the fridge to firm up a dose that melted in transit, and that melting does not alter the active ingredients. QUAD's liquid skips that handling step, which is a convenience gain rather than a potency one.

Customization: Rugiet offers physician-customizable dosing — your doctor can adjust the ratio of each ingredient based on your response. QUAD offers clinician-guided dosing but with less granular customization documented publicly. For men who need highly specific titration, this may be a consideration.

For a full comparison, see our Rugiet vs BlueChew vs QUAD comparison review.

QUAD vs BlueChew Gold: The Oxytocin Problem

BlueChew Gold launched in early 2026 as BlueChew's premium 4-ingredient offering: sildenafil, tadalafil, apomorphine, and oxytocin. That formula is unchanged. QUAD's is not, so the comparison has shifted.

The two products now share sildenafil and tadalafil, and diverge completely after that. Gold adds apomorphine and oxytocin. QUAD adds L-citrulline and PT-141. Both are making the same basic bet — that blood flow alone is not the whole problem — and the useful question is which one's second ingredient has evidence behind it.

The case against oxytocin for ED

Oxytocin is a neuropeptide associated with emotional bonding, trust, and social behavior. BlueChew markets it as supporting "emotional connection" and "deeper intimacy." However, there are two fundamental problems with including oxytocin in a sublingual ED tablet.

First, sublingual oxytocin has extremely poor bioavailability. Published research shows approximately 4.5% sublingual bioavailability with "10-fold variation" between individuals. The same research concluded that sublingual delivery "would not seem a reliable route" for administering oxytocin therapeutically. Even intranasal oxytocin — the more common research delivery method — achieves only 11% bioavailability.

Second, there are no published randomized controlled trials showing oxytocin improves erectile function. Some preliminary work suggests oxytocin may play a role in sexual behavior, but it has never been approved for, or clinically validated as, an ED treatment.

The case for PT-141 (QUAD's choice)

PT-141 is not a clean win either, and we are not going to pretend otherwise. It is not FDA-approved for ED in men, and its use in a compounded formula is off-label. But the comparison is not "PT-141 versus an approved drug" — it is PT-141 versus oxytocin, because both products are reaching for the same thing: an ingredient that acts on desire rather than blood flow.

On that comparison PT-141 is ahead on every axis that matters. It has early-phase human trial data in men, including erectogenic effects in some sildenafil non-responders. It carries an FDA approval in another indication (Vyleesi, 2019, for HSDD in premenopausal women). Oxytocin delivered sublingually has roughly 4.5% bioavailability, 10-fold variation between individuals, and no published RCTs for ED at all.

The Liquid Format Advantage

A recurring gripe about Rugiet Ready in user reviews is soft or melted troches. Rugiet asks you to store them in a cool, dry place at room temperature (74°F/23°C) or below, and in warm environments they can soften or melt outright. Two things are worth getting right about this, because it is widely overstated. Refrigeration is not a standing requirement — Rugiet's instruction is that if a dose melts in transit and the blister pack is intact, you refrigerate it until it firms up and then take it as normal. And Rugiet states that melting or freezing does not alter the active ingredients; excessive heat affects the tablet's texture and handling, not the medicine. So the cost of a soft troche is hassle, not a wasted dose.

QUAD's sublingual liquid has nothing to soften, so that hassle does not arise. It can be stored at room temperature, carried in a pocket or bag, and measured precisely for each dose. That is a real convenience advantage — but be clear about its size: it saves you a handling annoyance, it does not rescue a degraded medication, because by the manufacturer's own account Rugiet's medication is not degraded.

The liquid format also offers a pharmacokinetic advantage. Liquid sublingual absorption is generally faster and more consistent than solid troches or dissolving tablets, because the active ingredients are already in solution and do not need to dissolve first. MEDVi puts onset at roughly 10–15 minutes; individual response varies. The reformulation added a taste claim here too — MEDVi says the new version tastes better, which for something you hold under your tongue is a fair thing to care about.

Side Effects and Safety

QUAD contains four active ingredients, two of them PDE5 inhibitors. Based on the clinical literature for the individual components:

Common: nasal congestion, mild headache, facial flushing, dizziness. These are standard PDE5 inhibitor side effects and typically diminish with regular use.

Less common: back pain, upset stomach, temporary visual changes such as blue-tinted vision.

Rare but serious: dangerously low blood pressure (especially if combined with nitrate medications), priapism (erection lasting more than 4 hours), sudden changes in hearing or vision. These require immediate medical attention.

Nausea: the PT-141 side effect nobody is telling you about

This is the most likely unpleasant thing you will experience on QUAD, and most reviews of the new formula skip it entirely. PT-141's own FDA-approved product, Vyleesi, lists nausea as its most common adverse reaction by a wide margin: 40% of patients in the pooled phase 3 trials, versus 1% on placebo. Flushing affected 20% and headache 11%.

Two details matter more than the headline number. First, nausea is heavily front-loaded — it was reported by 21% of patients after the first dose and dropped to roughly 3% on subsequent doses. Second, it is short: median onset within an hour of dosing, lasting about two hours. In the trials, 13% of patients took an anti-emetic alongside it, and 8% stopped treatment because of it.

The practical read: expect the first dose to be the rough one, take it when you do not need to be anywhere, and raise it with the prescriber if it persists past the first few uses. It is worth knowing that QUAD's previous formula had a nausea problem too — apomorphine is also strongly associated with it — so this is less a new drawback than a relocated one.

One further point specific to the new formula deserves attention rather than a footnote. Bremelanotide's development for erectile dysfunction was halted in part over blood-pressure concerns — it produces a transient rise — and that is precisely the axis on which PDE5 inhibitors also act, in the opposite direction. It is contraindicated in uncontrolled hypertension and known cardiovascular disease. This is a real reason the ingredient is prescriber-supervised rather than something you can buy off a shelf, and a real reason to be upfront with the prescribing clinician about your blood pressure and any cardiovascular history. Do not treat the online intake form as a formality.

Dosing is compounded and set by the prescribing physician, which is genuinely useful here — it allows each ingredient to be adjusted individually rather than forcing a fixed combination on everyone. It also means nobody, including us, can tell you what dose you would end up on.

Pricing and How to Order

MEDVi QUAD costs $119 per month, which includes the medication and clinician-guided dosing. The ordering process works through MEDVi's telehealth platform: you complete an online health assessment, a licensed clinician reviews your information, and if approved, your prescription ships directly to you.

For context, here is how QUAD's pricing compares to alternatives:

We have dropped the "cost per proven ingredient" math this page used to run, because after the reformulation it no longer means anything — you cannot divide a price by ingredients that are not all approved for the same purpose. The plainer version: QUAD is the most expensive option in this table, and it is the only one whose differentiator is a desire-pathway ingredient with human trial data. Whether that premium is worth paying depends entirely on whether desire, rather than blood flow, is the thing that is not working for you.

Who Is QUAD Best For?

Frequently Asked Questions

The Bottom Line

The reformulated QUAD is a more interesting product than the old one and an easier one to oversell. What it does well: it pairs two FDA-approved PDE5 inhibitors with an upstream nitric-oxide precursor and the best-evidenced desire-pathway ingredient anyone in this category is using. Every ingredient has published human clinical evidence for sexual function, and the liquid format still solves a real problem that affects competing products.

What it does not do: make all four ingredients approved ED drugs. L-citrulline's supporting trial is 24 men. PT-141 is approved for a different condition in a different population by a different route. Neither of those is a reason to dismiss the formula, but both are reasons to ignore any page telling you QUAD is "clinically proven" across the board — including the version of this page that ran before July 2026.

The other trade-off is newness, twice over. QUAD does not have the independent review history Rugiet Ready has accumulated since 2020, and the current formula has only existed since mid-July 2026, so nobody has meaningful long-run user feedback on it yet. If you weight track record, Rugiet is the conservative pick. If your problem is desire rather than blood flow, or you specifically want to avoid apomorphine, QUAD is now the only option here that fits.

Related Reviews